Edralbrutinib

N/A

Report date: 2023/05/29 14:46:39
NME

Base Information

Drug NameEdralbrutinib
Drug Alias NameTG-1701SHR-1459
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsAutoimmune DiseasesNephrosisGlomerulonephritis, Membranous +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co LtdJiangsu shengdi Medicine Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co LtdJiangsu Hengrui Medicine Co LtdReistone Biopharma Co Ltd +[4] 
Inactive CompaniesTg Therapeutics Inc
Active IndicationsNephrosisGlomerulonephritis, MembranousNeuromyelitis Optica +[7] 
Inactive IndicationsAutoimmune DiseasesLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A